[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ouro Medicines\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":67},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,44],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100610558",false,"NCT07229144","OM336 in Seropositive Autoimmune Diseases","An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Sjogren's Disease or Idiopathic Inflammatory Myopathy","Key Inclusion Criteria:\n\n* Diagnosis of active seropositive autoimmune disease\n* Relapsed\u002Frefractory after ≥2 prior\u002Fongoing treatments\n* Body weight ≥ 50 kg\n* Willing to comply with and study requirements and procedures\n\nKey Exclusion Criteria:\n\n* Previous treatment with a BCMA-targeted therapy\n* Clinically significant infection within 3 months of screening\n* Major surgery within 3 months of screening or planned during the study\n* Pregnant or breastfeeding","ALL","18 Years","75 Years",{"count":19,"type":20},39,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.",[26,27],"Sjogrens Disease","Idiopathic Inflammatory Myopathy (IIM)",[29,30],"OM336","Ouro","RECRUITING","2026-06-11",{"date":34,"type":35},"2026-06-15","ACTUAL",{"date":37,"type":35},"2025-10-01",{"date":39,"type":20},"2028-03",{"name":41,"class":42},"Ouro Medicines","INDUSTRY",1,{"id":45,"slug":4,"hasResults":10,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":50,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":61,"completionDateStruct":63,"leadSponsor":65,"locationsCount":66},"100599397","NCT07083960","OM336 in Autoimmune Cytopenias","An Open-Label, Phase 1b, Multiple Ascending Dose Study of OM336 in Participants With Active Autoimmune Cytopenias","Key Inclusion Criteria:\n\n* Active autoimmune cytopenia\n* Relapsed\u002Frefractory after ≥1 prior treatment\n* Body weight ≥ 55 kg\n* Willing to comply with and study requirements and procedures\n\nKey Exclusion Criteria:\n\n* Previous treatment with a BCMA-targeted therapy\n* Clinically significant infection within 3 months of screening\n* Major surgery or splenectomy within 3 months of screening or planned during the study\n* Pregnant or breastfeeding",{"count":51,"type":20},32,[23],"An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of subcutaneously dosed OM336 in adult participants with autoimmune cytopenias.",[55,56,57],"AIHA - Warm Autoimmune Hemolytic Anemia","AIHA - Cold Autoimmune Hemolytic Anemia","ITP - Immune Thrombocytopenia","2025-09-24",{"date":60,"type":35},"2025-09-30",{"date":62,"type":35},"2025-08-01",{"date":64,"type":20},"2027-09",{"name":41,"class":42},3,""]